

The advice of JCVI is made with reference to the UK immunisation programme and may not necessarily transfer to other epidemiological circumstances

Joint Committee on Vaccination and Immunisation

Update on deliberations regarding the use of Bexsero® meningococcal B vaccine in the UK

JCVI met on 11th/12th February 2014 to review the latest information on the cost-effectiveness analysis of the potential use of a serogroup B meningococcal (MenB) vaccine in the NHS immunisation programme.

This review included consideration of the comments received from stakeholders as part of a recent consultation process. JCVI recognises the importance of this issue and is taking great care to consider all of the available evidence. A formal statement, setting out the complex information presented and JCVI's conclusions will be released at the earliest possible opportunity and by 26th March 2014 at the latest.

JCVI

13 February 2014

Notes

1. The Joint Committee on Vaccination and Immunisation (JCVI) is an independent Departmental Expert Committee and a statutory body constituted for the purpose of advising the Secretary of State on *"The provision of vaccination and immunisation services being facilities for the prevention of illness"*.
2. The JCVI's terms of reference as agreed by the UK health departments are - *"To advise UK health departments on immunisations for the prevention of infections and/or disease following due consideration of the evidence on the burden of disease, on vaccine safety and efficacy and on the impact and cost effectiveness of immunisation strategies. To consider and identify factors for the successful and effective implementation of immunisation strategies. To identify important knowledge gaps relating to immunisations or immunisation programmes where further research and/or surveillance should be considered."*